Eli Lilly and Company has received approval from the US Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) to manage chronic musculoskeletal pain.
It has been established in studies that Cymbalta significantly reduced chronic low back pain and chronic pain due to osteoarthritis.
Cymbalta is a non-narcotic pain reliever and is indicated to be taken daily by people with chronic pain.
Although the exact mechanism in which Cymbalta reduces chronic musculoskeletal pain is not known, it is believed that Cymbalta works by enhancing the body’s natural pain suppressing system.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData